- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 8 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| 21.11.25 | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11.25 | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 20.11.25 | Inhibikase Therapeutics announces proposed public offering and pre-funded warrants | 1 | Seeking Alpha | ||
| 20.11.25 | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | 203 | GlobeNewswire (Europe) | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics GAAP EPS of -$0.13 | 2 | Seeking Alpha | ||
| 14.11.25 | Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity | 940 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08.25 | Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | 433 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 14.08.25 | Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | 292 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 27.03.25 | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 546 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 178,80 | +0,34 % | AbbVie platziert US-Dollar-Anleihe mit 4,750% Kupon | Stuttgart (www.anleihencheck.de) - Das US-amerikanische Biopharma-Unternehmen AbbVie (ISIN US00287Y1091/ WKN A1J84E) hat eine neue Unternehmensanleihe (ISIN US00287YEG08/ WKN A4ERCA) mit einem Volumen... ► Artikel lesen | |
| TEVA | 24,700 | -2,76 % | Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 | TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter... ► Artikel lesen | |
| EYEPOINT | 11,290 | -2,76 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| ORGANIGRAM GLOBAL | 1,180 | +5,36 % | Mit der Übernahme der deutschen Sanity Group will Organigram Global das Wachstum in Europa ankurbeln | Der große Hype um Cannabis-Aktien hat an der Börse zwar spürbar nachgelassen. Es gibt im Segment aber noch immer viel Wachstum zu sehen. Organigram Global konnte für das vergangenen Geschäftsjahr einen... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 1,900 | -5,94 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 10, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 62,00 | -4,62 % | Nektar Therapeutics: Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting | SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin... ► Artikel lesen | |
| AMARIN | 12,500 | -1,57 % | Amarin Corporation plc: Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline | ||
| ACHIEVE LIFE SCIENCES | 3,545 | +0,14 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 156,75 | -0,10 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,260 | -5,96 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 388,80 | -0,89 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| XORTX THERAPEUTICS | 0,375 | +7,76 % | XORTX Therapeutics Inc (3): XORTX Therapeutics proposes three director nominees | ||
| BRIDGEBIO PHARMA | 60,14 | -0,73 % | Mizuho raises BridgeBio Pharma stock price target on drug strength | ||
| OPUS GENETICS | 3,955 | +0,51 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 22,200 | -0,89 % | Rigel Pharmaceuticals, Inc.: Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,035 (-1,91 %) liegt der Kurs bei 1,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.